Jefferies Comments On ALMN QTc Analysis

Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) presented a positive QTc analysis (QTcI) of Byetta data the Street has been awaiting, “which implies less concerning QTc increases with higher exenatide doses,” Jefferies reports.

“We remain positive on upcoming Bydureon QTc data and prospects for regulatory approval,” Jefferies writes. “Separately, with the clinical hold on the metreleptin/pramlintide program, we see no material impact to our lipodystrophy estimates, and obesity sales are upside to our valuation.”

Amylin Pharmaceuticals closed Wednesday at $11.08.